Michael Deininger, MD, PhD

Professor and Chief of Hematology and Hematologic Malignancies
Department of Internal Medicine
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah

Dr. Michael Deininger received his medical degree from the University of Würzburg Medical School, Germany, and his PhD from Imperial College, London. He trained in internal medicine and hematology/oncology, and completed a fellowship in stem cell transplantation at the University of Leipzig Medical Center. Dr. Deininger is professor and chief of hematology and hematologic malignancies in the Department of Internal Medicine and the Huntsman Cancer Institute (HCI) at the University of Utah.

Dr. Deininger is a member of the Chronic Leukemia Working Party, American Society of Hematology, and American Society of Clinical Oncology. He has written almost 200 articles in peer-reviewed journals including Blood, Journal of Clinical Investigation and The New England Journal of Medicine, has co-authored many book chapters, and contributed to leading textbooks. He is a regular speaker at major international scientific meetings.

Dr. Deininger’s scientific focus is leukemia, specifically myeloproliferative neoplasms including chronic myeloid leukemia (CML). Current work in his lab is focused on understanding the role of the bone marrow microenvironment in leukemia drug resistance, discovering novel therapeutic targets, and developing more specific signal transduction inhibitors.

Last modified: September 17, 2018